Monday, April 16, 2012

Japan DPP-IV market to be most crowded - Sixth DPP-IV to be launched shortly

The Pharmaceutical Affairs and Food Sanitation Council’s First Committee on New Drugs  will meet on April 27 to discuss approval for Mitsubishi Tana be Pharma Corporation’s (MTPC) type 2 diabetes treatment -Tenelia (teneligliptin). Tenelia if approved, would be the sixth DPP-IV inhibitor in Japan. It takes about two months for the drug to receive the final approval once the PAFSC issues a positive recommendation. 

US has three DPP-IV's , while the EU currently has four DPP-IV's on the market.  Takeda's alogliptin is approved in Japan, but yet to be approved in the US and Europe.

Despite significant competition, Januvia continues to dominate this space. Besides a superior profile,  Merck is taking all the necessary steps to sustain its leadership position in the space.